Format

Send to

Choose Destination
See comment in PubMed Commons below
PLoS One. 2015 Jul 10;10(7):e0132449. doi: 10.1371/journal.pone.0132449. eCollection 2015.

Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer.

Author information

  • 1Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada; Department of Medicine, University of Toronto, Toronto, ON, Canada.
  • 2Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
  • 3Escuela de Enfermeria, Universidad de Salamanca, Salamanca, Spain.
  • 4Medical Oncology Department, Salamanca University Hospital, Salamanca, Spain.
  • 5Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • 6Servicio de CardiologĂ­a, Complejo Hospitalario de Salamanca, Salamanca, Spain.
  • 7Medical Oncology Department and Translational Research Unit, Albacete University Hospital, Albacete, Spain.

Abstract

PURPOSE:

To describe the clinical features and outcomes of estrogen receptor negative (ER-) and progesterone receptor positive (PgR+) breast cancer.

METHODS:

We retrospectively reviewed a well-characterized database of sequential patients diagnosed with early stage invasive breast carcinoma. Outcomes of interest were time to relapse (TTR) and overall survival (OS). Multivariable Cox proportional hazards analysis was conducted to assess the association of ER-/PgR+ with TTR and OS in comparison to ER+ and to ER- and PgR negative (ER-/PgR-) tumors irrespective of HER2 status. ER and PgR expression was conservatively defined as 10% or greater staining of cancer cells.

RESULTS:

815 patients were followed for a median of 40.5 months; 56 patients (7%) had ER-/PgR+, 624 (77%) had ER+ and 136 (17%) had ER-/PgR- phenotypes. Compared with ER+ tumors, ER-/PgR+ tumors were associated with younger age (50 versus 59 years, p=0.03), high grade (50% versus 24%, p<0.001) and more frequent HER2 overexpression/amplification (43% versus 14%, p<0.001). TTR for ER-/PgR+ was intermediate between ER+ and ER-/PgR- tumors, but was not significantly different from ER+ tumors. Recurrences in the ER-/PgR+ and ER-/PgR- groups occurred early in follow-up while in ER+ tumors recurrences continued to occur over the duration of follow-up. OS of ER-/PgR+ was similar to ER+ tumors and better than that of ER-/PgR- tumors.

CONCLUSIONS:

The ER-/PgR+ phenotype is associated with higher grade with HER2 overexpression/amplification and occurs more commonly in younger women. Risk of relapse and death more closely resembles ER+ than ER-/PgR- tumors suggesting this phenotype represents a group of more aggressive hormone receptor positive tumors.

PMID:
26161666
PMCID:
PMC4498889
DOI:
10.1371/journal.pone.0132449
[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Public Library of Science Icon for PubMed Central
    Loading ...
    Support Center